Summary & Overview
CPT 21925: Deep Soft-Tissue Biopsy of Back or Flank
CPT code 21925 represents a surgical biopsy of deep soft tissue in the back or flank performed to obtain a tissue specimen for pathological evaluation, most commonly to assess for malignancy or other abnormal cellular processes. The code captures a targeted diagnostic surgical procedure distinct from superficial or needle biopsies owing to depth and anatomical location. Nationwide, this procedure is an important diagnostic tool influencing treatment planning for suspected deep-seated masses.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, and common billing considerations. The publication also covers national benchmarks where available, typical billing patterns, and policy updates relevant to coding and coverage for deep soft-tissue biopsy procedures.
This summary is intended for providers, billing professionals, and policy analysts seeking a clear, national-level reference on the clinical and administrative implications of CPT code 21925. Data not available in the input is identified explicitly in the relevant sections that follow.
Billing Code Overview
CPT code 21925 describes a biopsy of deep soft tissue in the back or flank to obtain a tissue sample from a suspicious mass felt in deeper tissues. The procedure yields a specimen submitted for pathological analysis to evaluate for abnormal cells, including malignancy.
Service Type: Surgical biopsy / diagnostic procedure
Typical Site of Service: Hospital outpatient department or ambulatory surgery center; may also occur in an outpatient clinic setting equipped for minor surgical procedures
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient presents with a firm, deep-seated palpable mass in the posterior flank/back region noted on clinical exam and reported progressive enlargement. Imaging with ultrasound or MRI localizes a suspicious intramuscular or deep subcutaneous lesion measuring 2.5 cm with concerning features for neoplasm. The interventional surgeon or orthopedic/plastic surgeon schedules a deep soft tissue biopsy to obtain diagnostic tissue. In the pre-procedure workflow, informed consent is obtained, targeted imaging localization and marking are performed (ultrasound or CT guidance as indicated), and appropriate labs/coagulation studies are reviewed. Intra-procedure steps include sterile preparation of the back/flank, local anesthesia or conscious sedation as appropriate, image guidance if needed, and obtaining core or excisional deep tissue samples sent in formalin to pathology. Post-procedure care includes hemostasis, wound dressing, monitoring for bleeding or infection, and pathology result follow-up to guide oncologic management if malignancy is identified. Typical sites of service are an outpatient procedure suite, hospital minor procedure room, ambulatory surgery center, or interventional radiology suite. The service type is a diagnostic invasive procedure (deep soft tissue biopsy) to obtain tissue for histopathologic analysis.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Normal, additional procedural service | When this code is the primary procedure and performed without unusual circumstances. |